MANE · Veradermics, Inc
$101.40
+2.89 (+2.93%)
At close · Sep 8
Going-concern doubt
— cleared Aug 11, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. ... As of June 30, 2026, we had $819.9 million in cash, cash equivalents and marketable securities. We expect our existing cash, cash equivalents and marketable securities will enable the Company to meet its obligations for at least the twelve-month period from the date the financial statements are available to be issued.”View the 10-Q filed Aug 11, 2026
Market Cap
$4.12B
Shares
41.78M
MANE metrics
44 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$98.51
Market cap
$4.12B
Price action
19 metricsPrice change (1W)
+0.6%
Price change (30D)
-11.1%
Price change (3M)
+7.4%
Price change (6M)
+102.9%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
96.8%
Beta
0.9
RSI (14D)
41.3
Price vs SMA 50
-10.7%
Price vs SMA 200
—
Avg volume (3M)
714,743
Relative volume
0.5
Average dollar volume
$78.38M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
41.78M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.1
reciprocal yield 19.8%
FCF yield
-1.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$102.77M
Net income (TTM)
−$92.68M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5,330.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-11.4%
Return on assets
-11.2%
Debt / equity
—
Current ratio
70.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$78.33M
Quick ratio
70.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$319.33M
Latest balance sheet
Cash & equivalents
$319.33M
Total assets
$825.74M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$78.30M
Capital expenditures (TTM)
$26,000
R&D (TTM)
$75.82M
SG&A (TTM)
—
Stock compensation (TTM)
$9.89M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
164
13F filer change QoQ
+83
Institutional ownership
81.2%
Short interest
3 metricsShort interest
9.6%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
55 / 100
Insider activity
2 metricsNet insider buying (90D)
−$103.12M
Insider-sentiment score
11 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1827635
CUSIP
922967104
13F (30d)
118 filings
118 filers
Visit website
Investor relations